On May 21, 2012, Cardinal Health, Inc. (the "Company") issued and sold $250 million aggregate principal amount of 1.900% notes due 2017 (the "2017 Notes") and $250 million aggregate principal amount of 3.200% notes due 2022 (the "2022 Notes", and, together with the 2017 Notes, the "Notes"). In connection therewith, on May 16, 2012, the Company entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC, as representatives of the underwriters named in Schedule II thereto. The offering is being made pursuant to the Company's effective registration statement on Form S-3 (Registration Statement No. 333-169073) previously filed with the Securities and Exchange Commission (the "Registration Statement"). The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to the text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1 to this report.

The Notes are governed by an Indenture dated as of June 2, 2008 between the Company and The Bank of New York Mellon Trust Company, N.A., formerly known as The Bank of New York Trust Company, N.A. (the "Indenture"). The 2017 Notes are filed as Exhibit 4.1 to this report and the 2022 Notes are filed as Exhibit 4.2.

In connection with the issuance of the Notes, Rylan O. Rawlins, Associate General Counsel of the Company, and Shearman & Sterling LLP, counsel to the Company, have delivered opinions to the Company, regarding the legality of the Notes upon issuance and sale thereof. A copy of these opinions are attached as Exhibits 5.1 and 5.2 to this report.

The Company incorporates by reference the exhibits filed herewith into the Registration Statement, pursuant to which the Notes were registered.

(d) Exhibits

1.1 Underwriting Agreement, dated as of May 16, 2012, between Cardinal Health, Inc. and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith

        Incorporated and Morgan Stanley & Co. LLC, as representatives of the
        underwriters named in Schedule II thereto.

4.1     Form of 2017 Notes.

4.2     Form of 2022 Notes.

5.1     Opinion of Rylan O. Rawlins, Associate General Counsel of the Company.

5.2     Opinion of Shearman & Sterling LLP.

23.1    Consent of Rylan O. Rawlins, Associate General Counsel of the Company
        (included in Exhibit 5.1).

23.2    Consent of Shearman & Sterling LLP (included in Exhibit 5.2).